House dust mite allergy ultra-short course therapy - Allergy TherapeuticsAlternative Names: Acarovac MPL; Acarovac Quattro
Latest Information Update: 17 Feb 2017
At a glance
- Originator Allergy Therapeutics
- Class Allergy immunotherapies
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Allergic rhinitis